An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema
Open Access
- 22 June 2024
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-10
Abstract
Background: Hereditary angioedema (HAE) is characterized by unpredictable and often severe cutaneous and mucosal swelling that affects the extremities, face, larynx, gastrointestinal tract, or genitourinary area. Introduction of novel long-term prophylactic treatment options (lanadelumab, berotralstat, and C1-esterase inhibitor SC [human]) into the treatment armamentarium has substantially reduced HAE attacks, allowing patients to be attack free for longer with improvements to their quality of life. Using data drawn from a wide-ranging survey of patients with HAE, we examined the relationship between duration of time attack free and health-related quality of life (HRQoL), exploring the possibility that there is an association between observed improvement in HRQoL and attack-free duration. Methods: A survey among patients with HAE on long-term prophylaxis (LTP) in six countries (the US, Australia, Canada, UK, Germany, and Japan) assessed the relationship between attack-free duration and mean Angioedema Quality of Life (AE-QoL) scores, quality of life benefits, and rescue medication used. Analysis of covariance (ANCOVA) was used to assess the roles of LTP and attack-free period (< 1 month, 1– < 6 months, ≥ 6 months) on total AE-QoL scores. Results include descriptive p-values for strength of association, without control for multiplicity. Descriptive statistics were used to show the relationship between time attack free and quality of life benefits. Results: Longer durations of time for which participants reported being attack free at the time of the survey correlated with better AE-QoL scores and less use of rescue medication. The mean total AE-QoL scores were 51.8, 33.2, and 19.9 for those who reported having been attack free for < 1 month, 1– < 6 months, and ≥ 6 months, respectively, with higher scores reflecting more impairment. The ANCOVA results showed a strong association between attack-free duration and AE-QoL total score. Conclusion: This study shows that longer attack-free duration has an influential role for better HRQoL in patients receiving LTP. Prolonging the attack-free period is an important goal of therapy and recent advances in LTP have increased attack-free duration. However, opportunities exist for new treatments to further increase attack-free duration and improve HRQoL for all patients with HAE.Keywords
Funding Information
- CSL Behring
This publication has 28 references indexed in Scilit:
- Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacksAllergy, 2020
- Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United StatesAnnals of Allergy, Asthma & Immunology, 2017
- Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorNew England Journal of Medicine, 2017
- Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation processJournal of Allergy and Clinical Immunology, 2016
- The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important differenceAllergy, 2016
- Current state of hereditary angioedema management: A patient surveyAllergy and Asthma Proceedings, 2015
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- The elusive physiologic role of Factor XIIJournal of Clinical Investigation, 2008
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006